"Landiolol's Impact on Organ Failure in Septic Shock Patients"

A randomized clinical trial involving 126 patients with tachycardia and established septic shock found that the administration of landiolol intravenously to reduce heart rate did not significantly decrease organ failure as measured by the Sequential Organ Failure Assessment (SOFA) score in the 14 days after randomization. The trial was terminated early due to a signal of possible harm and the results do not support the use of landiolol for managing tachycardia among patients treated with norepinephrine for established septic shock.